Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.
作者信息
Aomar-Millán Ismael Francisco, Salvatierra Juan, Hernández-Quero José
机构信息
Department of Internal Medicine, San Cecilio University Hospital, Avda. del Conocimiento s/n, 18016, Granada, Spain.
Department of Rheumatology, San Cecilio University Hospital, Granada, Spain.
出版信息
Intern Emerg Med. 2021 Jun;16(4):1105-1106. doi: 10.1007/s11739-021-02690-3. Epub 2021 Mar 10.
Abstract
摘要
相似文献
1
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.在重度新型冠状病毒肺炎和中度炎症反应患者中，单用皮质类固醇或联合托珠单抗治疗后使用阿那白滞素：一项回顾性队列研究：回复
Intern Emerg Med. 2021 Jun;16(4):1105-1106. doi: 10.1007/s11739-021-02690-3. Epub 2021 Mar 10.
2
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.在重症 COVID-19 肺炎和中度炎症反应患者中，单独使用皮质类固醇或与托珠单抗联合使用阿那白滞素后的情况。一项回顾性队列研究：评论
Intern Emerg Med. 2021 Jun;16(4):1101-1103. doi: 10.1007/s11739-021-02663-6. Epub 2021 Feb 18.
3
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.早期识别 COVID-19 细胞因子风暴并使用阿那白滞素或托珠单抗治疗。
Int J Infect Dis. 2020 Oct;99:291-297. doi: 10.1016/j.ijid.2020.07.081. Epub 2020 Aug 6.
4
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.阿那白滞素治疗单独使用皮质类固醇激素或托珠单抗治疗重症 COVID-19 肺炎和中度炎症过度患者。一项回顾性队列研究。
Intern Emerg Med. 2021 Jun;16(4):843-852. doi: 10.1007/s11739-020-02600-z. Epub 2021 Jan 5.
5
Efficacy of anticytokine treatments added to corticosteroids in patients with COVID-19-associated pneumonia and hyperinflammation: a single center experience.在新型冠状病毒肺炎相关肺炎和炎症反应过度的患者中，在皮质类固醇基础上加用抗细胞因子治疗的疗效：单中心经验
Eur Rev Med Pharmacol Sci. 2022 Oct;26(19):7297-7304. doi: 10.26355/eurrev_202210_29924.
6
Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.312 例 SARS-CoV-2 所致中重度肺炎伴高炎症患者应用阿那白滞素和皮质类固醇治疗的特征和临床转归：一项回顾性队列研究。
PLoS One. 2023 Mar 24;18(3):e0283529. doi: 10.1371/journal.pone.0283529. eCollection 2023.
7
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.阿那白滞素联合甲泼尼龙治疗重症 COVID-19 肺炎和炎症过度激活患者：一项观察性队列研究。
J Allergy Clin Immunol. 2021 Feb;147(2):561-566.e4. doi: 10.1016/j.jaci.2020.11.006. Epub 2020 Nov 19.
8
Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.阿那白滞素治疗托珠单抗治疗抵抗的重症 COVID-19 的疗效：一项单中心回顾性对照研究。
Int J Infect Dis. 2021 Apr;105:319-325. doi: 10.1016/j.ijid.2021.02.041. Epub 2021 Feb 13.
9
The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.托珠单抗、阿那白滞素和泼尼松龙对 COVID-19 患者抗 SARS-CoV-2 抗体反应的影响：一项前瞻性队列研究，采用多变量分析影响抗体反应的因素。
Int J Infect Dis. 2021 Apr;105:756-762. doi: 10.1016/j.ijid.2021.03.031. Epub 2021 Mar 15.
10
Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness.阿那白滞素或大剂量皮质类固醇治疗低剂量地塞米松治疗后病情恶化的 COVID-19 肺炎患者：一项比较疗效的观察性研究。
Int J Infect Dis. 2023 Jan;126:87-93. doi: 10.1016/j.ijid.2022.11.017. Epub 2022 Nov 18.
本文引用的文献
1
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.在重症 COVID-19 肺炎和中度炎症反应患者中，单独使用皮质类固醇或与托珠单抗联合使用阿那白滞素后的情况。一项回顾性队列研究：评论
Intern Emerg Med. 2021 Jun;16(4):1101-1103. doi: 10.1007/s11739-021-02663-6. Epub 2021 Feb 18.
2
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
3
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.COVID-19 并发严重炎症性呼吸衰竭患者的早期白细胞介素-1 受体阻断。
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-18953. doi: 10.1073/pnas.2009017117. Epub 2020 Jul 22.
4
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
Zotero 插件